Biopharma Tetiana Kosten Biopharma Tetiana Kosten

Perspectives for integrating Ukraine’s API and generic drug production into supply of the EU Critical Medicines List

Discover how integrating Ukraine's API and generic drug production into the EU Critical Medicines List could boost the EU's pharmaceutical supply chain. Explore Ukraine's role in enhancing drug availability, strategic benefits, and the impact of technology transfer. Learn about current capabilities, market value, and future opportunities for building a technology transfer business case in pharma

Read More
Private Equity, Biopharma Tetiana Kosten Private Equity, Biopharma Tetiana Kosten

A development partner requires market research and due diligence on manufacturers of medical products

We helped the UN lead agency identify and qualify manufacturers of medical products to meet the growing demand in procurement. We conducted market research to identify companies and performed operational, legal, and technical due diligence to evaluate companies' eligibility for supply arrangements.

Read More